RBD COVID Vaccine Has Fast Response to Variants at Low Cost
COVID-19 Vaccine Platform
Tags: University of Melbourne, Australia, Healthcare & Lifesciences
The University of Melbourne's RBD-based SARS-CoV-2 vaccine platform focuses on generating COVID-19 vaccines targeting mutations in emerging variants. It aims to elicit immunity against variants that evade responses produced by current vaccines, utilizing the receptor-binding domain (RBD) of the spike protein. This approach promises temperature-stable vaccines at an affordable cost, addressing the need for second-generation vaccines against challenging SARS-CoV-2 variants. The platform has shown promising preclinical results, demonstrating safety, robust immunogenicity, and potent neutralizing activity across multiple animal models.
IP Type or Form Factor: Patent Pending; Platform
TRL: 6 - prototype validated in intended environment
Industry or Tech Area: Vaccines; Biotechnology
